NYSE: EVMNEvommune Inc Stock
$18.41-1.82 (-9%)
Updated Nov 7, 2025
EVMN Price
$18.41
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$16.70
52 Week High
$24.03
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.06
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EVMN's potential to beat the market
- EVMN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EVMN
RankedUnranked of 483
RankedUnranked of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.44 | A | |
| $105.98 | A | |
| $131.16 | A |
Be the first to know about important EVMN news, forecast changes, insider trades & much more!
EVMN News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EVMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVMN's short-term assets ($94.90M) exceed its short-term liabilities ($10.09M)
Short-term Liabilities Financials
EVMN's short-term assets ($94.90M) exceed its long-term liabilities ($347.00k)
Long-term Liabilities Financials
EVMN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more EVMN due diligence checks available for Premium users.
Valuation
EVMN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$96.2M
Liabilities
$10.4M
Debt to equity
-0.06
EVMN's short-term assets ($94.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVMN's short-term assets ($94.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVMN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EVMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Evommune Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.